feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Business and Economy / Ozempic Patents Expire: Generics Set to Slash Drug Costs Globally

Ozempic Patents Expire: Generics Set to Slash Drug Costs Globally

15 Jan

•

Summary

  • Ozempic patents are expiring worldwide, opening doors for generic competition.
  • Generic versions could lower the monthly cost of semaglutide to as low as $15.
  • Canada, China, India, and Brazil are among the first countries to see generic influx.
Ozempic Patents Expire: Generics Set to Slash Drug Costs Globally

The global patent expiration for semaglutide, the active ingredient in Ozempic and Wegovy, is set to dramatically increase worldwide access to the drug. Dozens of manufacturers are preparing to launch generic versions in numerous countries as patents lapse.

This competition is anticipated to trigger a significant price reduction, with monthly costs potentially falling to as low as $15 in some markets. Patients in countries like Canada, China, India, and Brazil, where patents are expiring, are expected to benefit first from this affordability.

While Novo Nordisk faces challenges from generic rivals and competitors like Eli Lilly, the company stated that patent expiry is a natural part of a drug's lifecycle and sees "substantial opportunities" for innovation. Regulators will face the challenge of monitoring the quality and side effects of these new generic versions entering the market.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Patents for semaglutide, the active ingredient in Ozempic, are beginning to expire in various countries, with major shifts expected in 2026.
Generic versions of semaglutide are expected to significantly reduce costs, potentially to as low as $15 per month in some regions.
Canada, China, India, and Brazil are among the key countries where generic competition for Ozempic is expected to emerge soon.

Read more news on

Business and Economyside-arrow
trending

JPMorgan Chase earnings beat

trending

Patriots defeat Chargers 16-3

trending

Leafs beat Avalanche in OT

trending

Anthropic launches Claude for Healthcare

trending

Clippers beat Hornets

trending

Red Wings honor Fedorov

trending

Malik Monk leads Kings surge

trending

Emma Raducanu Hobart debut

You may also like

Novo Nordisk: Oral GLP-1s to dominate market

13 Jan • 10 reads

article image

New Wegovy Pill Offers Injectable Efficacy in Daily Dose

5 Jan • 127 reads

article image

FDA Approves Oral Wegovy: Game Changer for Dieters?

23 Dec, 2025 • 170 reads

article image

Ozempic Knock-Offs: Are They Safe?

18 Dec, 2025 • 157 reads

article image

Weight-Loss Drugs Reshape Economy

1 Dec, 2025 • 246 reads